Alan D. D’andrea
#104,260
Most Influential Person Now
Alan D. D’andrea's AcademicInfluence.com Rankings
Alan D. D’andreamedical Degrees
Medical
#1272
World Rank
#1595
Historical Rank
Hematology
#15
World Rank
#16
Historical Rank
Oncology
#53
World Rank
#56
Historical Rank

Alan D. D’andreaphilosophy Degrees
Philosophy
#4177
World Rank
#6594
Historical Rank
Logic
#1694
World Rank
#2515
Historical Rank

Download Badge
Medical Philosophy
Alan D. D’andrea's Degrees
- Doctorate Medicine Harvard University
Why Is Alan D. D’andrea Influential?
(Suggest an Edit or Addition)Alan D. D’andrea's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (2005) (2933)
- Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. (2001) (1261)
- Biallelic Inactivation of BRCA2 in Fanconi Anemia (2002) (1222)
- Repair Pathway Choices and Consequences at the Double-Strand Break. (2016) (1020)
- Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells (1989) (818)
- The Fanconi anaemia/BRCA pathway (2003) (811)
- Identification of the FANCI Protein, a Monoubiquitinated FANCD2 Paralog Required for DNA Repair (2007) (688)
- Expression cloning of the murine erythropoietin receptor (1989) (661)
- How the fanconi anemia pathway guards the genome. (2009) (592)
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. (2015) (567)
- The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. (2005) (559)
- Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors (2003) (558)
- Regulation of monoubiquitinated PCNA by DUB autocleavage (2006) (520)
- Chromatin Remodeling at DNA Double-Strand Breaks (2013) (509)
- The Fanconi anaemia pathway: new players and new functions (2016) (488)
- Homologous recombination-deficient tumors are hyper-dependent on POLQ-mediated repair (2015) (487)
- Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. (2012) (487)
- Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. (2015) (480)
- S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. (2002) (477)
- Convergence of the Fanconi Anemia and Ataxia Telangiectasia Signaling Pathways (2002) (476)
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer (2016) (462)
- Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (445)
- Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor (1990) (438)
- Positional cloning of a novel Fanconi anemia gene, FANCD2. (2001) (433)
- DNA Damage and Repair Biomarkers of Immunotherapy Response. (2017) (418)
- ATR couples FANCD2 monoubiquitination to the DNA-damage response. (2004) (416)
- The Fanconi Anemia/BRCA pathway: new faces in the crowd. (2005) (411)
- Molecular pathogenesis of Fanconi anemia: recent progress. (2006) (386)
- Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. (2005) (381)
- Susceptibility pathways in Fanconi's anemia and breast cancer. (2010) (380)
- A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer (2017) (365)
- Functional Interaction of Monoubiquitinated FANCD2 and BRCA2/FANCD1 in Chromatin (2004) (345)
- A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. (2007) (338)
- Expanded roles of the Fanconi anemia pathway in preserving genomic stability. (2010) (324)
- Somatic ERCC2 Mutations Are Associated with a Distinct Genomic Signature in Urothelial Tumors (2016) (306)
- The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. (2005) (278)
- Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways (1997) (278)
- Interaction of FANCD2 and NBS1 in the DNA damage response (2002) (278)
- Deubiquitinating enzymes: a new class of biological regulators. (1998) (277)
- The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains (1991) (276)
- DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. (2006) (274)
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. (2019) (272)
- Mechanisms of PARP inhibitor sensitivity and resistance. (2018) (270)
- UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. (2006) (268)
- Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. (2012) (265)
- Fanconi Anemia Proteins FANCA, FANCC, and FANCG/XRCC9 Interact in a Functional Nuclear Complex (1999) (260)
- BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. (2012) (256)
- Molecular pathogenesis and clinical management of Fanconi anemia. (2012) (253)
- COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION (2011) (253)
- Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. (2009) (245)
- Regulation of DNA repair by ubiquitylation (2006) (243)
- Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. (2018) (235)
- Human erythropoietin receptor: cloning, expression, and biologic characterization. (1990) (229)
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance (2013) (226)
- The Fanconi Anemia Pathway in Cancer. (2019) (224)
- EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation (2017) (221)
- Induction of tyrosine phosphorylation by the erythropoietin receptor correlates with mitogenesis (1991) (216)
- Molecular biology of Fanconi anemia: implications for diagnosis and therapy. (1997) (213)
- Inhibition of homologous recombination by the PCNA-interacting protein PARI. (2012) (212)
- Friend spleen focus-forming virus glycoprotein gp55 interacts with the erythropoietin receptor in the endoplasmic reticulum and affects receptor metabolism. (1990) (207)
- The Fanconi anaemia proteins, FAA and FAC interact to form a nuclear complex (1997) (207)
- Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway (2006) (202)
- Synthetic lethality between CCNE1 amplification and loss of BRCA1 (2013) (195)
- Cell cycle-dependent chromatin loading of the Fanconi anemia core complex by FANCM/FAAP24. (2008) (193)
- Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. (2004) (192)
- Fanconi anemia and DNA repair. (2001) (189)
- WRN Helicase is a Synthetic Lethal Target in Microsatellite Unstable Cancers (2018) (187)
- CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. (2016) (182)
- UAF1 Is a Subunit of Multiple Deubiquitinating Enzyme Complexes* (2009) (180)
- The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. (2016) (176)
- Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. (2007) (173)
- DUB-1, a deubiquitinating enzyme with growth-suppressing activity. (1996) (169)
- TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. (2020) (167)
- Chk1-Mediated Phosphorylation of FANCE Is Required for the Fanconi Anemia/BRCA Pathway (2007) (161)
- Erythropoietin receptor and interleukin-2 receptor β chain: A new receptor family (1989) (158)
- Erythropoietin receptor. Subunit structure and activation. (1990) (158)
- Mouse beta-globin DNA-binding protein B1 is identical to a proto-oncogene, the transcription factor Spi-1/PU.1, and is restricted in expression to hematopoietic cells and the testis (1993) (157)
- XPF-ERCC1 Participates in the Fanconi Anemia Pathway of Cross-Link Repair (2009) (152)
- Menin associates with FANCD2, a protein involved in repair of DNA damage. (2003) (150)
- DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells (2018) (147)
- Complementation analysis in Fanconi anemia: assignment of the reference FA-H patient to group A. (2000) (145)
- Regulation of Rev1 by the Fanconi Anemia Core Complex (2011) (145)
- Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. (2005) (145)
- A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy (2012) (143)
- Mouse models of Fanconi anemia. (2009) (141)
- Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9. (2001) (141)
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. (2019) (141)
- Overcoming reprogramming resistance of Fanconi anemia cells. (2012) (140)
- Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer (2020) (139)
- Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. (2005) (139)
- The Fanconi anemia polypeptide FACC is localized to the cytoplasm. (1994) (139)
- FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair. (2016) (138)
- The fanconi anemia pathway requires FAA phosphorylation and FAA/FAC nuclear accumulation. (1998) (137)
- Functional Activity of the Fanconi Anemia Protein FAA Requires FAC Binding and Nuclear Localization (1998) (136)
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer (2018) (135)
- The fanconi anemia proteins FANCA and FANCG stabilize each other and promote the nuclear accumulation of the Fanconi anemia complex. (2000) (135)
- Phosphorylation of FANCD2 on Two Novel Sites Is Required for Mitomycin C Resistance (2006) (131)
- Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells (2013) (126)
- PCNA Ubiquitination Is Important, But Not Essential for Translesion DNA Synthesis in Mammalian Cells (2011) (126)
- A novel diagnostic screen for defects in the Fanconi anemia pathway. (2002) (125)
- CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors (2009) (125)
- Knockdown of zebrafish Fancd2 causes developmental abnormalities via p53-dependent apoptosis. (2003) (125)
- BRCA1 interacts directly with the Fanconi anemia protein FANCA Folias A et al. (2002) Hum Mol Genet 11: 2591–2597 (2002) (124)
- The FANCM/FAAP24 complex is required for the DNA interstrand crosslink-induced checkpoint response. (2010) (123)
- TGF-β Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. (2016) (121)
- Human ELG1 Regulates the Level of Ubiquitinated Proliferating Cell Nuclear Antigen (PCNA) through Its Interactions with PCNA and USP1* (2010) (121)
- The Fanconi anemia polypeptide, FAC, binds to the cyclin-dependent kinase, cdc2. (1997) (116)
- Biomarker-Guided Development of DNA Repair Inhibitors. (2020) (114)
- Cytokinesis failure occurs in Fanconi anemia pathway-deficient murine and human bone marrow hematopoietic cells. (2010) (114)
- DUB-2 Is a Member of a Novel Family of Cytokine-inducible Deubiquitinating Enzymes* (1997) (111)
- Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets. (2019) (110)
- Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. (2009) (109)
- DNA damage responses and their many interactions with the replication fork. (2006) (108)
- DNA Polymerase POLN Participates in Cross-Link Repair and Homologous Recombination (2009) (106)
- The USP1/UAF1 Complex Promotes Double-Strand Break Repair through Homologous Recombination (2011) (105)
- Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins. (1997) (104)
- A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. (2015) (103)
- Fanconi anemia pathway (2017) (103)
- HSP90 Shapes the Consequences of Human Genetic Variation (2017) (103)
- Biallelic inactivation of REV7 is associated with Fanconi anemia. (2016) (103)
- Hematopoietic Stem Cell Defects in Mice with Deficiency of Fancd2 or Usp1 (2010) (102)
- The Fanconi road to cancer. (2003) (101)
- Regulation of the Fanconi anemia pathway by a SUMO-like delivery network. (2011) (101)
- The Fanconi anemia core complex is required for efficient point mutagenesis and Rev1 foci assembly. (2008) (101)
- Clinical variability of Fanconi anemia (type C) results from expression of an amino terminal truncated Fanconi anemia complementation group C polypeptide with partial activity. (1996) (97)
- Structural Basis of Rev1-mediated Assembly of a Quaternary Vertebrate Translesion Polymerase Complex Consisting of Rev1, Heterodimeric Polymerase (Pol) ζ, and Pol κ* (2012) (95)
- A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors (2021) (94)
- Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer (2016) (91)
- Analysis of somatic microsatellite indels identifies driver events in human tumors (2017) (90)
- Regulation of the Fanconi anemia pathway by monoubiquitination. (2003) (88)
- Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage. (2010) (88)
- The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition (2019) (88)
- Structure and transcription of the mouse erythropoietin receptor gene (1990) (87)
- The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of FANCC. (2002) (87)
- The Fanconi anemia/BRCA pathway: a coordinator of cross-link repair. (2006) (87)
- Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models* (2016) (87)
- Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. (2020) (87)
- The interplay of Fanconi anemia proteins in the DNA damage response. (2004) (86)
- Natural gene therapy in monozygotic twins with Fanconi anemia. (2006) (86)
- Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants. (2002) (85)
- WDR20 Regulates Activity of the USP12·UAF1 Deubiquitinating Enzyme Complex* (2010) (84)
- Chromatin recruitment of DNA repair proteins: lessons from the fanconi anemia and double-strand break repair pathways. (2008) (83)
- ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer (2018) (83)
- Erythropoietin receptor signals both proliferation and erythroid-specific differentiation. (1993) (82)
- The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents (2007) (82)
- Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression (2017) (82)
- Direct DNA Binding Activity of the Fanconi Anemia D2 Protein* (2005) (81)
- The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner. (1996) (80)
- The erythropoietin receptor transmembrane region is necessary for activation by the Friend spleen focus-forming virus gp55 glycoprotein (1992) (79)
- The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. (2001) (78)
- TRIP13 regulates DNA repair pathway choice through REV7 conformational change (2020) (77)
- CtIP-Mediated Fork Protection Synergizes with BRCA1 to Suppress Genomic Instability upon DNA Replication Stress. (2018) (77)
- Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer (2019) (77)
- Regulated degradation of FANCM in the Fanconi anemia pathway during mitosis. (2009) (76)
- Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. (1994) (76)
- Bi‐allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia (2003) (74)
- The effect of the Fanconi anemia polypeptide, FAC, upon p53 induction and G2 checkpoint regulation. (1996) (71)
- Spectrum of mutations in the Fanconi anaemia group G gene, FANCG/XRCC9 (2000) (71)
- Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy (2010) (71)
- MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability (2014) (68)
- Friend erythroleukemia revisited. (2000) (67)
- Pineocytomas of childhood a reappraisal of natural history and response to therapy (1987) (66)
- The Fanconi Anemia/BRCA Signaling Pathway: Disruption in Cisplatin-Sensitive Ovarian Cancers (2003) (66)
- Inhibition of the Nedd8 System Sensitizes Cells to DNA Interstrand Cross-linking Agents (2012) (65)
- USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors. (2018) (65)
- Dedicated to the core: understanding the Fanconi anemia complex. (2006) (65)
- A dominant negative erythropoietin (EPO) receptor inhibits EPO-dependent growth and blocks F-gp55-dependent transformation (1994) (62)
- FANCD2 activates transcription of TAp63 and suppresses tumorigenesis. (2013) (62)
- Familial and congenital polycythemia in three unrelated families. (1992) (62)
- The WD40 Repeats of FANCL Are Required for Fanconi Anemia Core Complex Assembly* (2006) (60)
- Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. (2003) (60)
- The murine DUB-1 gene is specifically induced by the betac subunit of interleukin-3 receptor (1996) (60)
- Erythropoietin-induced cellular differentiation requires prolongation of the G1 phase of the cell cycle. (1995) (59)
- Molecular Pathogenesis of Fanconi Anemia (2002) (58)
- Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin (2012) (57)
- RAD18-dependent Recruitment of SNM1A to DNA Repair Complexes by a Ubiquitin-binding Zinc Finger* (2010) (55)
- XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck (2011) (54)
- Erythropoietin activates Raf1 by an Shc-independent pathway in CTLL-EPO-R cells. (1997) (54)
- Subtyping Analysis of Fanconi Anemia by Immunoblotting and Retroviral Gene Transfer (1998) (53)
- Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer (2013) (52)
- Response to erythropoietin in erythroid subclones of the factor-dependent cell line 32D is determined by translocation of the erythropoietin receptor to the cell surface. (1991) (52)
- JAK2 is required for induction of the murine DUB-1 gene (1997) (50)
- Molecular biology of Fanconi anemia. (1997) (50)
- Transcriptional repressor ZBTB1 promotes chromatin remodeling and translesion DNA synthesis. (2014) (49)
- Cooperation of the NEIL3 and Fanconi anemia/BRCA pathways in interstrand crosslink repair (2020) (49)
- Normal cellular radiosensitivity in an adult Fanconi anaemia patient with marked clinical radiosensitivity. (2001) (48)
- The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange. (2001) (47)
- DUB-2A, a new member of the DUB subfamily of hematopoietic deubiquitinating enzymes. (2001) (47)
- A common epitope is shared by activated signal transducer and activator of transcription-5 (STAT5) and the phosphorylated erythropoietin receptor: implications for the docking model of STAT activation. (2001) (47)
- Allosteric Activation of Ubiquitin-Specific Proteases by β-Propeller Proteins UAF1 and WDR20. (2016) (47)
- Mutation in the negative regulatory element of the erythropoietin receptor gene in a case of sporadic primary polycythemia. (1994) (47)
- Preclinical protocol for in vivo selection of hematopoietic stem cells corrected by gene therapy in Fanconi anemia group C. (2001) (45)
- Association of the erythropoietin receptor with protein tyrosine kinase activity. (1992) (44)
- Soluble thrombopoietin receptor (Mpl) and granulocyte colony-stimulating factor receptor directly stimulate proliferation of primitive hematopoietic progenitors of mice in synergy with steel factor or the ligand for Flt3/Flk2. (1996) (43)
- A patient-derived mutant form of the Fanconi anemia protein, FANCA, is defective in nuclear accumulation. (1999) (42)
- Inactivation of Uaf1 Causes Defective Homologous Recombination and Early Embryonic Lethality in Mice (2013) (42)
- Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells. (2001) (41)
- Marrow failure. (2002) (40)
- Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection. (2020) (40)
- Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation. (1992) (39)
- Bactericidal/Permeability-Increasing Protein (rBPI21) and Fluoroquinolone Mitigate Radiation-Induced Bone Marrow Aplasia and Death (2011) (39)
- Assignment of the erythropoietin receptor (EPOR) gene to mouse chromosome 9 and human chromosome 19. (1990) (39)
- Structural Determinants of Human FANCF Protein That Function in the Assembly of a DNA Damage Signaling Complex* (2007) (39)
- Erythropoietin receptor and interleukin-2 receptor beta chain: a new receptor family. (1989) (38)
- Activation of Hif1α by the Prolylhydroxylase Inhibitor Dimethyoxalyglycine Decreases Radiosensitivity (2011) (38)
- Hematopoietic growth factors and the regulation of differentiative decisions. (1994) (38)
- Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma (2016) (37)
- RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway. (2015) (36)
- Carboxy terminal region of the Fanconi anemia protein, FANCG/XRCC9, is required for functional activity. (2000) (36)
- Nijmegen breakage syndrome diagnosed as Fanconi anaemia (2005) (34)
- A new nuclease member of the FAN club (2010) (34)
- Impaired DNA double strand break repair in cells from Nijmegen breakage syndrome patients. (2006) (34)
- Crosstalk between the nucleotide excision repair and Fanconi anemia/BRCA pathways. (2014) (33)
- PARI overexpression promotes genomic instability and pancreatic tumorigenesis. (2013) (32)
- DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer (2010) (32)
- A new hematopoietic growth factor receptor superfamily: structural features and implications for signal transduction. (1990) (31)
- Fusion of the erythropoietin receptor and the Friend spleen focus-forming virus gp55 glycoprotein transforms a factor-dependent hematopoietic cell line (1993) (31)
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. (2018) (30)
- Targeting DNA repair and the cell cycle in glioblastoma (2012) (30)
- Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors (2021) (30)
- The Carboxyl Terminus of FANCE Recruits FANCD2 to the Fanconi Anemia (FA) E3 Ligase Complex to Promote the FA DNA Repair Pathway* (2014) (30)
- Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9. (2001) (29)
- Bone marrow-derived mesenchymal stem cells suppress t cell activation without inducing allogeneic anergy (2000) (28)
- USP9X inhibition promotes radiation-induced apoptosis in non-small cell lung cancer cells expressing mid-to-high MCL1 (2015) (28)
- Exploiting the Microhomology-Mediated End-Joining Pathway in Cancer Therapy (2020) (28)
- A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines. (1996) (27)
- Cytokine receptors in congenital hematopoietic disease. (1994) (27)
- Receptors that induce erythroid differentiation of Ba/F3 cells: structural requirements and effect on STAT5 binding. (1997) (27)
- PCNA-Dependent Cleavage and Degradation of SDE2 Regulates Response to Replication Stress (2016) (27)
- The molecular and cellular biology of Fanconi anemia. (1999) (27)
- MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia. (2020) (27)
- DNA Repair Deficiency and Immunotherapy Response. (2018) (27)
- Human MutS and FANCM complexes function as redundant DNA damage sensors in the Fanconi Anemia pathway. (2011) (26)
- Inhibition of receptor binding and neutralization of bioactivity by anti-erythropoietin monoclonal antibodies. (1990) (26)
- Production of tumor necrosis factor and other proinflammatory cytokines by human mononuclear phagocytes stimulated with myelin P2 protein. (1993) (26)
- BRCA1: a missing link in the Fanconi anemia/BRCA pathway. (2013) (25)
- Anti-erythropoietin receptor (EPO-R) monoclonal antibodies inhibit erythropoietin binding and neutralize bioactivity. (1993) (25)
- Genetic analysis of ionizing radiation-induced mutagenesis in Saccharomyces cerevisiae reveals TransLesion Synthesis (TLS) independent of PCNA K164 SUMOylation and ubiquitination. (2006) (25)
- Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML (2020) (24)
- Nuclear localization of the Fanconi anemia protein FANCC is required for functional activity. (1999) (24)
- Upregulation of Fanconi Anemia DNA Repair Genes in Melanoma Compared to Non-Melanoma Skin Cancer (2011) (24)
- A cytoplasmic serine protein kinase binds and may regulate the Fanconi anemia protein FANCA. (2001) (23)
- Erythropoietin receptor: cloning strategy and structural features. (1990) (22)
- FANCD2 Hurdles the DNA Interstrand Crosslink (2009) (22)
- Targeting DNA repair pathways in AML. (2010) (22)
- Subunit Structure and Activation (1990) (21)
- To the rescue: the Fanconi anemia genome stability pathway salvages replication forks. (2012) (20)
- Fanconi anaemia forges a novel pathway (1996) (20)
- CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress. (2020) (20)
- The molecular physiology of erythropoietin and the erythropoietin receptor. (1994) (19)
- Knockdown of Zebrafish Fancd 2 Causes Developmental Abnormalities via p 53-Dependent Apoptosis (2003) (19)
- Predictive Potential of Head and Neck Squamous Cell Carcinoma Organoids. (2019) (19)
- The interaction of the erythropoietin receptor and gp55. (1992) (19)
- Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer (2020) (18)
- Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors (2020) (17)
- MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity (2021) (16)
- A senataxin-associated exonuclease SAN1 is required for resistance to DNA interstrand cross-links (2018) (16)
- Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia (2019) (15)
- Results from MAGENTA: A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counseling during online testing for breast and ovarian cancer genetic risk. (2020) (15)
- p31comet promotes homologous recombination by inactivating REV7 through the TRIP13 ATPase (2020) (15)
- Cellular function of the Fanconi anemia pathway (2001) (15)
- Activation of the erythropoietin receptor in stable lymphoid and myeloid transfectants. (1991) (14)
- Differentiation Domains of the Erythropoietin Receptor (1994) (14)
- Subtyping of Fanconi anemia patients: implications for clinical management. (2003) (14)
- Molecular mimicry of erythropoietin by the spleen focus-forming virus gp55 glycoprotein: the first stage of Friend virus-induced erythroleukemia. (1992) (14)
- Targeting replication stress in cancer therapy (2022) (14)
- Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers (2015) (13)
- A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer (2021) (12)
- Regulated Binding of the Fanconi Anemia Proteins, FANCA and FANCC (1999) (12)
- Stressed out: endogenous aldehydes damage hematopoietic stem cells. (2012) (12)
- Functional analysis of Fanconi anemia mutations in China. (2018) (12)
- REV7 directs DNA repair pathway choice. (2021) (12)
- Analysis of cis-acting sequences and trans-acting factors regulating the interleukin-3 response element of the DUB-1 gene. (1999) (12)
- Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer (2021) (11)
- NF-κB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair (2018) (11)
- Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours (2021) (10)
- Ubiquitin recognition by FAAP20 expands the complex interface beyond the canonical UBZ domain (2014) (10)
- The Protexin complex counters resection on stalled forks to promote homologous recombination and crosslink repair. (2021) (10)
- FANCM: A landing pad for the Fanconi Anemia and Bloom's Syndrome complexes. (2009) (10)
- Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells (2021) (10)
- Biallelic inactivation of REV7 is associated with Fanconi anemia. (2017) (10)
- Functional profiling of nucleotide Excision repair in breast cancer. (2019) (9)
- DNA damage discrimination at stalled replication forks by the Rad5 homologs HLTF and SHPRH. (2011) (9)
- Tumor infiltrating and peritumoral T cells and expression of PD-L1 in BRCA1/2-mutated high grade serous ovarian cancers. (2015) (9)
- Regulated binding of the Fanconi anemia proteins, FANCA and FANCC. (1999) (8)
- A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy. (2009) (8)
- A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo. (1997) (8)
- Association of POLE-mutated and MSI endometrial cancers with an elevated number of tumor-infiltrating and peritumoral lymphocytes and higher expression of PD-L1. (2015) (8)
- Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer (2016) (7)
- Abstract 2796: Development of a RAD51-based assay for determining homologous recombination proficiency and PARP inhibitor sensitivity (2017) (7)
- Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. (2022) (7)
- Menin Associates with FANCD 2 , a Protein Involved in Repair of DNA Damage 1 (2003) (7)
- In vivo synergism between PARP-inhibitor olaparib and HSP90-inhibitor AT13387 in high grade serous ovarian cancer patient derived xenografts. (2016) (7)
- Abstract CT232: Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumors (2019) (7)
- Chapter 4 – DNA Repair Pathways and Human Cancer (2008) (6)
- Cellular Responses to DNA Damage and Human Chromosome Instability Syndromes (1998) (6)
- Inhibition of TGFβ1 and TGFβ3 promotes hematopoiesis in Fanconi anemia. (2020) (6)
- Abstract CT047: Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors (2017) (6)
- Inhibition of the Nedd 8 system sensitizes cells to DNA Inter-strand crosslinking agents (2012) (6)
- Disassembly of the Shieldin Complex by TRIP13 (2020) (6)
- Targeting DNA repair with combined inhibition of NHEJ and MMEJ induces synthetic lethality in TP53-mutant cancers. (2022) (6)
- Of Escherichia coli and Man: Understanding Glioma Resistance to Temozolomide Therapy (2009) (5)
- Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer (2020) (5)
- Tumor-derived Lysophosphatidic Acid Blunts Protective Type-I Interferon Responses in Ovarian Cancer. (2022) (5)
- Erythropoietin Receptor Contains both Growth‐promoting Activity and Differentiation‐promoting Activity a (1994) (5)
- Abstract 1788: The CDK inhibitor dinaciclib sensitizes triple-negative breast cancer cells to PARP inhibition. (2013) (5)
- The C-Terminus of c-Abl Is Required for Proliferation and Viability Signaling in a c-Abl/Erythropoietin Receptor Fusion Protein (1998) (5)
- Metformin for treatment of cytopenias in children and young adults with Fanconi anemia (2021) (4)
- Genomic Landscape of Primary and Recurrent Anal Squamous Cell Carcinomas in Relation to HPV Integration, Copy-Number Variation, and DNA Damage Response Genes (2021) (4)
- Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2-mutant metastatic breast cancer (MBC). (2019) (4)
- Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort (2017) (4)
- Case records of the Massachusetts General Hospital. Case 13-2006. A 50-year-old man with a painful bone mass and lesions in the liver. (2006) (4)
- The C-terminus of c-ABL is required for proliferation and viability signaling in a c-ABL/erythropoietin receptor fusion protein. (1998) (4)
- Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (4)
- Subunit structure and transmembrane signaling of the erythropoietin receptor. (1992) (4)
- FANCI functions as a repair/apoptosis switch in response to DNA crosslinks. (2021) (4)
- Aldehydes Pose a Threat to BRCA2 Mutation Carriers (2017) (4)
- CHAMP1 binds to REV7/FANCV and promotes homologous recombination repair (2022) (3)
- New insights from Fanconi anemia (2003) (3)
- Structure and function of the erythropoietin receptor in stable erythropoietin-dependent transfectants. (1991) (3)
- Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma (2021) (3)
- Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with distinct homologous recombination deficiency associated DNA aberration profiles (2021) (3)
- Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. (2021) (2)
- Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer (2022) (2)
- A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer. (2020) (2)
- DNA repair protein biomarkers in triple negative breast cancer. (2009) (2)
- Abstract IA12: Targeting DNA repair in cancer therapy (2017) (2)
- The cytokine-activated tyrosine kinase JAK 2 activates Raf-1 in a p 21 ras-dependent manner ( signal transduction / baculovirus / mammalian cells / oncogenes ) (2005) (2)
- HAUSP hunting the FOX(O) (2006) (2)
- Somatic ERCC2 Mutations Are Associated With a Distinct Mutational Signature in Muscle-Invasive Bladder Cancer (2016) (2)
- Studies on the production of proinflammatory cytokines and on the modulation of gene expression for some NADPH oxidase components by phagocytosing human neutrophils (1993) (2)
- DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells (2018) (2)
- Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer (2020) (2)
- Cloning and Functional Analysis of Erythropoietin‐, Interleukin‐3‐and Thrombopoietin‐Inducible Genes (1996) (2)
- Abstract 2540: Identification of factors governing sensitivity of NSCLC cell lines to inhibition of Poly (ADP-Ribose) Polymerase (PARP) (2012) (2)
- Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC) (2021) (2)
- Abstract 4189: Homologous recombination pathway-based biomarkers for treatment of non-small cell lung cancer with PARP inhibitors (2017) (1)
- Abstract 368A: Functional assessment of DNA damage repair defects and the anti-tumor immune response in high grade serous ovarian cancers using patient-derived organoids (2019) (1)
- Cytokinesis Failure In Fanconi Anemia Pathway Deficient Hematopoietic Cells (2010) (1)
- VIEWS IN THE SPOTLIGHT BRCA 1 : A Missing Link in the Fanconi Anemia / BRCA Pathway (2013) (1)
- Abstract 3882: Compromised Cdk1 activity sensitizes BRCA-proficient cancer cells to inhibition of Poly(ADP-ribose) polymerase (2010) (1)
- Genomic Analysis of Chemoradiation Therapy Response in Anal Carcinoma (2015) (1)
- STAG2 Mutations Alter Cohesin Ring Function and Provide Therapeutic Vulnerabilities in Acute Myeloid Leukemia (2018) (1)
- Isolation of human and murine hematopoietic stem cells for DNA damage and DNA repair assays (2021) (1)
- Correction: Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy (2011) (1)
- CCAR2 functions downstream of the Shieldin complex to promote double-strand break end-joining (2022) (1)
- 238 Reversal of primary and acquired PARP-inhibitor resistance in BRCA-mutated triple-negative breast cancers by inhibition of transcriptional cyclin-dependent kinases (CDKs) (2014) (1)
- Abstract 4287: Whole-genome CRISPR/Cas9 screen of the CHK1 inhibitor prexasertib implicates FAM122A loss as a potential resistance mechanism (2018) (1)
- Crystal structure of Human FancF Protein that Functions in the Assembly of a DNA Damage Signaling Complex (2006) (1)
- Gene-Correction Rescues Reprogramming of Fanconi Anemia Fibroblasts and Enables Hematopoietic Differentiation of FA Induced Pluripotent Stem Cells in Vitro and In Vivo (2011) (1)
- Abstract 1787: Identification of factors governing sensitivity of NSCLC cell lines to inhibition of Poly (ADP-Ribose) Polymerase (PARP). (2013) (1)
- Amendment history : Corrigendum ( March 2017 ) Biallelic inactivation of REV 7 is associated with Fanconi anemia (2019) (1)
- DNA Repair Biomarkers in Rectal Cancer (2008) (1)
- Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin (2012) (1)
- Refolding of the isolated extracellular domain of the erythropoietin receptor. (1994) (1)
- Abstract GMM-027: DYNLL1 INHIBITS DNA END RESECTION IN BRCA1-DEFICIENT CELLS AND REGULATES PARP INHIBITOR SENSITIVITY (2019) (1)
- Relieving the Itch (1998) (1)
- Abstract IA15: PARP inhibitor resistance and acquired vulnerability in breast cancer (2018) (0)
- Abstract AP22: DNA DAMAGE RESPONSES AND IMMUNE PROFILING THROUGH HIGHLY MULTIPLEXED TISSUE IMMUNOFLUORESCENCE (T-CYCIF) IN HIGH-GRADE SEROUS OVARIAN CANCER (2019) (0)
- Vulnerability in Ovarian Cancer (2017) (0)
- Hyperactive Non-Canonical TGF-β Pathway Signaling in Fanconi Anemia Bone Marrow Stromal Cells Contributes to Growth Suppression (2016) (0)
- Functional Interaction between FANCD2 and ATM in the DNA Damage Response. (2005) (0)
- Molecular Oncology: DNA repair inhibition in anti-cancer therapeutics (2013) (0)
- Regulation of the Fanconi Anemia/BRCA pathway (2005) (0)
- Abstract 2979: Combined cdk1 and PARP inhibition results in tumor regression in a KrasG12D p53L/L murine lung adenocarcinoma model (2011) (0)
- A senataxin-associated exonuclease SAN1 is required for resistance to DNA interstrand cross-links (2018) (0)
- Abstract 2729: Estrogen receptor-negative breast cancer cell lines exhibit hypersensitivity to the CHK1 inhibitor LY2606368 (2016) (0)
- Characterization Of Full-Length, Recombinant Amsh, USP9x, and USP1: Clinically-Relevant Deubiquitinases Involved In Hematological Malignancies (2013) (0)
- Abstract IA05: Fanconi's anemia: Emerging therapeutic opportunities (2014) (0)
- Interval Salpingectomy and Delayed Oophorectomy Versus Risk-Reducing Salpingo-Oophorectomy in Women at Risk for Hereditary Ovarian Carcinoma: A Prospective Multi-Site Trial (2020) (0)
- Abstract CN05-02: Novel mechanisms of PARP inhibitor resistance (2018) (0)
- Abstract 1448: Whole genome RNAi screen identifies proteasome inhibition as a strategy for NSCLC radiosensitization (2012) (0)
- Whole Genome RNAi Screens Identify USP9X Inhibition as a Strategy for NSCLC Radiosensitization (2014) (0)
- Abstract IA002: Inherited DNA repair defects and premature aging (2023) (0)
- Proteasome inhibition in high-grade glioma treatment: A strategy for simultaneous tumoricidal activity, temolozamide chemosensitization, and radiation sensitization (2008) (0)
- Abstract PR4: Regulation of the Fanconi anemia pathway by a SUMO-like delivery network (2011) (0)
- Reply to “Involvement of oxidative stress in Fanconi's anaemia: from phenotype to FA protein functions” (2003) (0)
- Abstract SY29-02: Novel mechanisms of PARP inhibitor resistance (2017) (0)
- Abstract POSTER-BIOL-1331: Nucleotide excision repair mutations confer sensitivity to platinum but not PARP-inhibitors in epithelial ovarian cancer (2015) (0)
- Crystal structure of the UAF1/WDR20/USP12 complex (2016) (0)
- Circulating MicroRNA Profiling for Thoracic Radiation Therapy Biomarkers (2015) (0)
- Mapping the Functional Landscape of ERCC2 Mutations in Muscle-Invasive Bladder Cancer (2017) (0)
- Exploiting Homologous Recombination Defects in N on-Small Cell Lung Cancer Through Combined PARP and Wee1 Inhibition. (2016) (0)
- A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC). (2022) (0)
- Abstract 1620: ATR inhibition for the treatment of ATM-deficient gastric cancer (2018) (0)
- Abstract SY28-01: Targeting DNA repair pathways in cancer therapy (2010) (0)
- Abstract LB-280: The landscape of somatic microsatellite indels across cancer: detection and identification of driver events (2017) (0)
- Screening of small molecule inhibitors of the Fanconi Anemia-BRCA pathway (2005) (0)
- Use of XPF expression in tumors and XPF single nucleotide polymorphisms to predict clinical outcome in head and neck cancer. (2010) (0)
- erythropoietin binding and neutralize bioactivity Anti-erythropoietin receptor (EPO-R) monoclonal antibodies inhibit (2011) (0)
- Abstract 1650: Whole-genome RNAi screen identified BCAS1 as a novel modifier of non-small cell lung carcinoma radioresistance (2016) (0)
- Structure of the erythropoietin receptor in stable fibroblast transfectants. (1990) (0)
- FANCC The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of (2013) (0)
- Fanconi Anemia: Emerging Therapeutic Opportunities (2012) (0)
- Diamond-Blackfan anemia and nucleolar transport (2003) (0)
- Abstract 5725: The USP1 inhibitor I-138 kills BRCA1-deficient tumor cells and overcomes PARP inhibitor resistance (2023) (0)
- Fanconi anemia and bone marrow failure (2015) (0)
- Chabner Colloquium: Answering the Big Questions in Cancer Research & 2017 STO Annual Meeting (2017) (0)
- REV7/FANCV Binds to CHAMP1 and Promotes Homologous Recombination Repair (2021) (0)
- Crystal structure of free Ubiquitin-specific protease 12 (2016) (0)
- Predictive Biomarkers and Personalized Medicine XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck (2011) (0)
- Abstract PL05-02: Synthetic Lethal Interaction between Homologous Recombination Repair and POLQ-mediated Alternative End-Joining (2015) (0)
- Dynamics of the DYNLL1/MRE11 complex regulates DNA end resection and recruitment of the Shieldin complex to DSBs (2023) (0)
- The Fanconi Pathway in Pediatric T-Cell Acute Lymphoblastic Leukemia (2017) (0)
- Rapid assessment of fanconi pathway function: A new diagnostic approach to fanconi anemia (2000) (0)
- The Fanconi Anemia Pathway Induces Senescence and Suppresses Tumorigenesis in Vivo (2013) (0)
- Perspectives Erythropoietin Receptor Subunit Structure and Activation (2013) (0)
- Abstract 333: USP1 is required for replication fork stability in BRCA1-deficient tumors (2018) (0)
- Mechanisms of Resistance to Reprogramming of Cells Defective In the Fanconi Anemia DNA Repair Pathway (2010) (0)
- Abstract 2052: TRIP13 amplification confers PARP inhibitor resistance and polymerase theta inhibitor sensitivity (2021) (0)
- Abstract AP10: REAL-TIME ASSESSMENT OF HGSC DNA DAMAGE REPAIR DEFECTS AND DEFECT-INDUCED RESPONSE TO THERAPY IN OVARIAN CANCER ORGANOIDS (2019) (0)
- anemia protein FANCA A cytoplasmic serine protein kinase binds and may regulate the Fanconi (2013) (0)
- Abstract CN05-02: Targeting the Fanconi anemia/BRCA pathway in cancer therapy. (2011) (0)
- Requirements and Effect on STAT5 Binding Receptors That Induce Erythroid Differentiation of Ba/F3 Cells: Structural (2013) (0)
- Cell cycle-dependent chromatin loading of the Fanconi anemia core complex by FANCM/FAAP24. Commentary (2008) (0)
- blocks F-gp55-dependent transformation. receptor inhibits EPO-dependent growth and A dominant negative erythropoietin (EPO) (2013) (0)
- Abstract IA9: Targeting the Fanconi anemia/BRCA pathway in cancer therapy (2011) (0)
- buffering role of HSP 90 in disease manifestations d HSP 90 chaperoning shapes allele expressivity (2017) (0)
- Crystal structure of the UAF1/USP12 complex in F222 space group (2016) (0)
- Isolation of cytokine-inducible genes from hematopoietic cells by differential display. (1997) (0)
- Abstract 2747: Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer (2021) (0)
- Abstract C74: Stabilization of mutant BRCA1 confers PARP inhibitor and platinum resistance. (2013) (0)
- Bone Marrow Failure Secondary to Cytokinesis Failure (2015) (0)
- Bone Marrow Failure in Fanconi Anemia from Hyperactive TGF-β Signaling (2014) (0)
- The Murine DUB-1 Gene Is Specifically Induced by the (cid:98) c Subunit of the Interleukin-3 Receptor (1996) (0)
- Abstract 6208: Targeting DNA polymerase theta and ATM leads to synergistic killing of mantle cell lymphoma cells (2023) (0)
- Abstract 796: Dual inhibition of NHEJ and MMEJ induces synthetic lethality in TP53 mutant cancers (2022) (0)
- Hematopoietic Stem Cell Defects in Novel Fanconi Anemia Mouse Models (2008) (0)
- Abstract PR06: Dissecting mechanisms of replication fork stabilization in patient-derived high-grade serous organoid cultures and their impact on therapeutic sensitivity and the immune-tumor interaction (2020) (0)
- TRIP13 regulates DNA repair pathway choice through REV7 conformational change (2020) (0)
- TGF-β Pathway Inhibition Rescues the Function of Hematopoietic Stem and Progenitor Cells Derived from Patients with Fanconi Anemia (2015) (0)
- PARP1 inhibition selectively radiosensitized malignant gliomas with hyperactive EGFR (2008) (0)
- Crystal structure of WD repeat-containing protein 20 (2016) (0)
- Abstract PR18: Somatic ERCC2 mutations, nucleotide excision repair (NER) function, and cisplatin response in muscle-invasive bladder cancer (MIBC) (2017) (0)
- Dissecting the Mechanisms of Drug Resistance in BRCA1/2-Mutant Breast Cancers (2017) (0)
- Modifier genetics in zebrafish identify Chk1 and an associated survival pathway as targets for pharmacotherapy of MDS/AML with P53 mutations. (2006) (0)
- Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer (2020) (0)
- TGFβ pathway is required for viable gestation of Fanconi anemia embryos (2022) (0)
- Abstract IA04: Targeting DNA repair in ovarian cancer therapy. (2016) (0)
- Genomic features of primary and recurrent anal squamous cell carcinoma. (2016) (0)
- Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer (2023) (0)
- Abstract CN05-02: Targeting the Fanconi anemia/BRCA pathway. (2013) (0)
- NF-κB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair (2018) (0)
- The IL-2 Induced De-Ubiquitinating Enzyme, DUB-2, Is a Nuclear-Cytoplasmic Shuttle Which Requires Catalytic Activity for Nuclear Localization. (2006) (0)
- Abstract 2751: Fanconi anemia pathway and DNA repair-based prognostic signatures in ovarian cancer (2011) (0)
- Abstract 4487: Association of the tumor-immune microenvironment with response to niraparib and pembrolizumab in relapsed, platinum-resistant ovarian cancer (2019) (0)
- Abstract IA10: Fanconi anemia and novel drug targets (2014) (0)
- Abstract 1403: PCNA-dependent cleavage and degradation of SDE2 regulates response to replication stress (2017) (0)
- THE FANCONI ANEMIA POLYPEPTIDE, FAC, NORMALIZES p53 INDUCTION IN A TRANSFECTED HEMATOPOIETIC CELL LINE. • 930 (1996) (0)
- Molecular pathogenesis of Fanconi anemia : recent progress. Commentary (2006) (0)
- Abstract A04: Profiling DNA damage repair and immunophenotypes in BRCA1/2 mutated high-grade serous ovarian cancers (2018) (0)
- Monoubiquitinated FANCD2 Is Both Necessary and Sufficient for Mitomycin C Resistance in the Absence of a Functional Fanconi Anemia Core Complex. (2004) (0)
- A Small Interfering Ribonucleic Acid-based Approach to Characterize Brain Tumor Resistance to Radiation Therapy: 893 (2006) (0)
- Abstract IA17: PARP inhibitor resistance in prostate cancer (2018) (0)
- Human ELG1 regulates the level of monoubiquitinated PCNA through interactions with PCNA, USP1, and polymerase η (2009) (0)
- Abstract 1583: Proteasome inhibition as a strategy for non-small cell lung carcinoma via inhibition of DNA double strand break repair. (2013) (0)
- Abstract 3336: NF-κB inhibition by DMAPT radiosensitizes non-small cell lung carcinoma by impairing DNA double strand break repair (2015) (0)
- Cytokinesis Failure in Fanconi Anemia Pathway Deficient Murine Hematopoietic Stem Cells. (2009) (0)
- Targeting Epidermal Growth Factor Receptor Overexpression in Glioblastoma Multiforme by Inhibition of DNA Repair876 (2007) (0)
- Abstract IA25: Novel mechanisms of PARP-inhibitor resistance in tumors with defects in the Fanconi Anemia/BRCA pathway (2017) (0)
- Small Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells and Cause Cytotoxicity (2013) (0)
- Targeting EGFRvIII oncogenic over-expression by ATM inhibition (2007) (0)
- Abstract 1318: Proteasome and Fanconi Anemia/BRCA pathways as prognostic determinants of glioblastoma response to radiation and temozolomide: a proposed clinical trial (2010) (0)
- Abstract 1764: Overexpression of the DNA repair regulator PARI in pancreatic cancers promotes genomic instability and tumorigenesis. (2013) (0)
- Abstract 6190: Polymerase theta inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in BRCA-deficient cancers (2023) (0)
- Abstract 1644: NF-κB inhibitor DMAPT blocks non-homologous end-joining repair of radiation-induced DSBs in NSCLC (2016) (0)
- Targeting Fanconi Anemia / BRCA Pathway Defects in Cancer Therapeutics (2007) (0)
- WRN helicase is a synthetic lethal target in microsatellite unstable cancers (2019) (0)
- A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer. (0)
- Sensitivity of tumor cells deficient in the fanconi anemia pathway to inhibition of ataxia telangiectasia mutated (ATM) (2007) (0)
- Structure and Transcription of the Mouse Erythropoietin (0)
- Abstract 139: DNA damage and immunoprofiling with highly multiplexed tissue immunofluorescence (t-CycIF) in high-grade serous ovarian cancer (2018) (0)
- Abstract 23: Somatic mutation of cancer susceptibility genes in acute myeloid leukemia (2014) (0)
- Fanconi Anemia Pathway and Cancer Susceptibility (2001) (0)
- Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer (2014) (0)
- DNA REPAIR DEFECTS DRIVE GENOMIC INSTABILITY AND TUMOR IMMUNOGENICITY (2017) (0)
- Preclinical Models of DNA Repair Deficiency in Prostate Cancer (2018) (0)
This paper list is powered by the following services: